KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBITDA Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBITDA Margin for 16 consecutive years, with 20.56% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 7945.0% to 20.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.58%, a 2073.0% decrease, with the full-year FY2025 number at 33.58%, down 2073.0% from a year prior.
  • EBITDA Margin was 20.56% for Q4 2025 at Halozyme Therapeutics, down from 61.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 68.19% in Q2 2021 to a low of 20.56% in Q4 2025.
  • A 5-year average of 47.27% and a median of 52.06% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 6970bps in 2021, then tumbled -7945bps in 2025.
  • Halozyme Therapeutics' EBITDA Margin stood at 55.42% in 2021, then fell by -26bps to 41.05% in 2022, then increased by 7bps to 43.92% in 2023, then skyrocketed by 34bps to 58.89% in 2024, then crashed by -135bps to 20.56% in 2025.
  • Per Business Quant, the three most recent readings for HALO's EBITDA Margin are 20.56% (Q4 2025), 61.51% (Q3 2025), and 62.15% (Q2 2025).